Loading clinical trials...
Loading clinical trials...
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Conditions
Interventions
CHIKV VLP/adjuvant
Placebo
Locations
47
United States
Optimal Research, LLC
Huntsville, Alabama, United States
Alliance for Multispecialty Research - Mobile
Mobile, Alabama, United States
Alliance for Multispecialty Research, LLC
Tempe, Arizona, United States
Velocity Clinical Research, Banning
Banning, California, United States
Optimal Research, LLC
San Diego, California, United States
Lynn Institute of the Rockies
Colorado Springs, Colorado, United States
Start Date
September 29, 2021
Primary Completion Date
April 3, 2023
Completion Date
April 3, 2023
Last Updated
August 30, 2024
NCT05349617
NCT02861586
NCT02562482
Lead Sponsor
Bavarian Nordic
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions